null - FindTrial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2020-002849-42-FR

Enrollment

144

Registered

2021-02-22

Start date

2021-04-21

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 21.0 Level: LLT Classification code 10081091 Term: Lumbar radicular pain System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10076578 Term: Lumbosacral radiculopathy System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.1 Level: LLT Classification code 10066256 Term: Lumbar disc herniation System Organ Class: 100000004859

Interventions

Trade Name: GABAPENTINE Product Name: GABAPENTINE Pharmaceutical Form: Capsule Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 96 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 48

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactClinical trial associate

GROUPEMENT DES HOPITAUX DE L'INSTITUT CATHOLIQUE DE LILLE

URM@ghicl.net+33320225269

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026